Ameluz® PDT Shows Positive Phase 2b Results for Acne, Paving Way for Broader Market
BFRI sits 66% above its 52-week low of $0.536 on light trading volume (0.1× avg).
Summary
Biofrontera Inc. reported positive Phase 2b clinical trial results for its Ameluz® Photodynamic Therapy in treating moderate to severe acne vulgaris. The study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT compared to vehicle, identifying a 3-hour incubation regimen as the most promising protocol. This news, released via press release, precedes a formal 8-K filing confirming the same information. These positive results are a significant development for the company, as they support the further development of Ameluz® for a new, large market indication, potentially broadening the product's commercial scope. Traders will now monitor the company's plans for advancing Ameluz® into Phase 3 trials for acne vulgaris.
At the time of this announcement, BFRI was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $0.54 to $1.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.